1. People's Republic of China Stocks

  2. •

    Healthcare

  3. •

    Medical - Pharmaceuticals
China BCT Pharmacy Group, Inc.

China BCT Pharmacy Group, Inc.

CNBI
China BCT Pharmacy Group, Inc.US flagOther OTC
0.00
USD
+0.00
- -
686,778.00Market Cap
China BCT Pharmacy Group, Inc.
CNBI
(Other OTC)

Recent

price

0.00

P/E

ratio

- -

div

yld

- -

ROIC.AI

2008
2009
2009
2010
2011
2012
TTM
FRC
- -
- -
4.25
5.28
6.75
6.34
6.22
Revenue per Share
-0.01
- -
0.61
0.67
0.72
0.55
0.33
Basic EPS, GAAP
- -
- -
0.21
0.41
-0.24
-0.4
-0.39
Free Cash Flow per Basic Share
- -
- -
- -
- -
- -
0.04
- -
Dividend per Share
-0.01
-0.01
1.05
1.51
2.16
2.55
2.63
Book Value per Share
- -
0.01
1.21
1.8
2.67
3.15
3.26
Tangible Book Value per Share
3
5
32
38
38
38
38
Basic Weighted Avg Shares
- -
- -
136
201
257
242
237
Sales/Revenue/Turnover
- -
- -
19.8
17.62
16.39
12.15
9.81
Operating Margin (%)
- -
- -
1
1
1
2
2
Depreciation Expense
- -
- -
19
26
31
21
17
Net Income, GAAP
- -
- -
24.39
26.13
26.14
26.23
24.89
Effective Tax Rate (%)
- -
- -
14.26
12.79
12.11
8.7
7.06
Profit Margin (%)
- -
- -
30
53
110
126
131
Working Capital
- -
- -
4
2
- -
- -
- -
LT Debt
- -
- -
53
83
117
134
139
Total Equity
- -
- -
60.73
31.75
27.44
15.47
11.89
Return on Invested Capital (%)
- -
- -
87.44
45.68
39.72
21.32
16.32
Return on Capital (%)
- -
- -
- -
56.34
39.02
23.42
13.4
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
Sep'12
Dec'12
Mar'13
ST Debt
11
16
16
LT Borrowings
- -
- -
- -
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
38
38
38
Market Capitalization
25
8
10

Working Capital

FRC

•

in mil. unless spec.
Sep'12
Dec'12
Mar'13
Total Current Assets
194
200
216
Cash, Cash Equivalents & STI
19
22
23
Accounts Receivable, Net
142
146
149
Inventories
19
14
17
Total Current Liabilities
67
73
85
Payables & Accruals
56
54
69
ST Debt
11
16
16
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
38,130.16%
15.23%
Free Cash Flow
- -
-6,963.84%
66.52%
Net Income, GAAP
- -
-25,631.79%
-32.51%
Sales/Revenue/Turnover
- -
- -
-6.07%
Total Cash Common Dividend
- -
- -
-138.56%

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2011
59
65
67
66
257
2012
71
61
55
54
242
2013
67
- -
- -
- -
- -

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2011
0.15
0.19
0.22
- -
0.72
2012
0.2
0.13
0.08
- -
0.55
2013
0.09
- -
- -
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2011
- -
- -
- -
- -
- -
2012
- -
- -
- -
- -
0.04
2013
- -
- -
- -
- -
- -
Similar Companies
Gujarat Terce Laboratories Limited (GUJTERC.BO)
Relevium Technologies Inc. (RLLVF)
Walgreens Boots Alliance, Inc. (0LSZ.L)
Kiaro Holdings Corp. (KO.V)
Sotac Pharmaceuticals Ltd. (SOTAC.NS)
Tyche Industries Limited (TYCHE.BO)
Business
China BCT Pharmacy Group, Inc. (CNBI) operates as an integrated pharmaceutical company in the People's Republic of China, engaging in pharmaceutical distribution, retail pharmacy, and manufacturing through its wholly-owned subsidiaries Liuzhou BCT, Hefeng Pharmaceutical, and BCT Retail; Liuzhou BCT wholesales approximately 8,000 pharmaceutical and healthcare products including branded and generic prescription medicines, over-the-counter medicines, Western and Chinese medicines, personal care products, medical supplies, Chinese herbs, and medical instruments to hospitals, retail drug stores, clinics, medical centers, and individuals; BCT Retail manages a network of directly owned stores under the Baicaotang brand primarily in Guangxi province, offering prescription medicines, over-the-counter medicines, Chinese herbal medicine, roughly processed Chinese herbal medicine, family planning products, and other healthcare items with professional pharmaceutical services; Hefeng Pharmaceutical manufactures and sells generic and clinical drugs under the Asio brand such as traditional anti-inflammatory and antibacterial drugs, cancer treatment drugs, cardiovascular disease drugs, hepatitis drugs, Levodopa, Tabellae Sarcandrae, Rotandine Sulfate, Corydalis Saxicola Bunting, and Ethacridine Lactate injection. The company, founded in 1956 and headquartered at No. 102 Chengzhan Road, Liuzhou City, Guangxi Province, China, primarily serves the domestic market with a focus on Guangxi province. While no major acquisitions, partnerships, funding rounds, or strategic shifts have been reported in the last 1-2 years, the company maintains its established operational model amid a broader landscape of increased US pharma licensing activity with Chinese biotechs in 2025.